Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kochar, D.K.
Right arrow Articles by Garg, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kochar, D.K.
Right arrow Articles by Garg, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2004; 97: 33-38
© Association of Physicians 2004; all rights reserved.

Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study

D.K. Kochar, N. Rawat, R.P. Agrawal, A. Vyas1, R. Beniwal2, S.K. Kochar and P. Garg

From the Departments of Medicine, 1Neurology, and 2Preventive and Social Medicine, SP Medical College, Bikaner, India

Received 7 April 2003 and in revised form 8 October 2003

Background: Various drugs are effective in the management of painful diabetic neuropathy, but none is completely satisfactory. We previously found sodium valproate to be effective and safe in a short-term study.

Aim: To test the effectiveness and safety of sodium valproate in the management of painful diabetic neuropathy over 3 months.

Design: Randomized double-blind placebo-controlled study.

Methods: Consecutive attending patients with type 2 diabetes mellitus with painful neuropathy were asked to participate in the trial: 48 agreed. Five were excluded: three with HbA1c > 11, one with too low a pain level and one who withdrew consent. The remaining 43 were given either drug (group A) or placebo (group B). Each patient was assessed clinically. Quantitative assessment of pain was done by McGill Pain Questionnaire, Visual Analogue Score and Present Pain Intensity, at the beginning of the study, after 1 month and after 3 months. Motor and sensory nerve conduction velocities were measured initially and after 3 months. Liver function tests and other adverse drug-related effects were assessed periodically.

Results: Of the 43 patients, four dropped out: one in group A and three in group B. There was significant improvement in pain score in group A, compared to group B, at 3 months (p < 0.001). Changes in electrophysiological data were not significant. The drug was well-tolerated by all patients, except one, who had raised serum AST and ALT levels after 1 month of treatment, and whose treatment was discontinued.

Discussion: Sodium valproate is well-tolerated, and provides significant subjective improvement in painful diabetic neuropathy.

Address correspondence to Professor D.K. Kochar, C-54, Sadul Ganj, Bikaner (Raj) 334 003, India. e-mail: drdkkochar{at}indiatimes.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. DiabetesHome page
M. M. Huizinga and A. Peltier
Painful Diabetic Neuropathy: A Management-Centered Review
Clin. Diabetes, January 1, 2007; 25(1): 6 - 15.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.